Table 6.
Management and outcomes of patients admitted to PMH/PCH in 2018
| Total | Periorbital | Other | |
| (n=206) | (n=46) | (n=160) | |
| Duration of intravenous antibiotics, days, median (IQR) | 2 (2–3) | 3 (2–3) | 2 (2–3) |
| Intravenous antibiotic, n (%) | n=199 | n=45 | n=154 |
| Flucloxacillin | 154 (77.4) | 41 (91.1) | 113 (73.3) |
| Cefotaxime | 2 (1.0) | 2 (4.4) | |
| Ceftriaxone | 47 (23.6) | 41 (91.1) | 6 (3.9) |
| Cefazolin | 38 (19.1) | 5 (11.1) | 33 (21.4) |
| Clindamycin | 10 (5.0) | – | 10 (6.5) |
| Cotrimoxazole | 2 (1.0) | – | 2 (1.3) |
| Benzylpenicillin | 1 (0.5) | – | 1 (0.6) |
| Piperacillin/tazobactam | 15 (7.5) | 4 (8.9) | 11 (7.1) |
| Vancomycin | 27 (13.6) | 2 (4.4) | 25 (16.2) |
| Other | 3 (1.5) | – | 3 (1.9) |
| Duration of oral antibiotics, days, median (IQR) | 6 (5–7) | 7 (5–8) | 5 (5–7) |
| Oral antibiotic on discharge, n (%) | n=192 | n=42 | n=150 |
| Flucloxacillin | 20 (10.4) | 1 (2.4) | 19 (12.7) |
| Cephalexin | 103 (53.6) | 13 (30.9) | 90 (60.0) |
| Clindamycin | 8 (4.2) | 1 (2.4) | 7 (4.7) |
| Cotrimoxazole | 20 (10.4) | 2 (4.8) | 18 (12.0) |
| Amox/clav duo forte | 37 (19.3) | 24 (57.1) | 13 (8.7) |
| Amoxicillin | 2 (1.0) | 1 (2.4) | 1 (0.7) |
| Other | 4 (2.1) | – | 4 (2.7) |
| Total duration of antibiotic therapy, median (IQR) | 8 (7–10) | 9 (8–11) | 8 (7–10) |
| Surgery, n (%) | 52 (25.2) | – | 52 (32.5) |
| Duration of admission, median (IQR) | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Discharged to HITH, n (%) | 16 (7.8) | 9 (19.6) | 7 (4.4) |
| Follow up with paediatrician documented, n (%) | 80 (38.8) | 15 (32.6) | 65 (40.6) |
HITH, hospital in the home; PCH, Perth Children’s Hospital; PMH, Princess Margaret Hospital for Children.